Loxo Oncology (NASDAQ:LOXO)

CAPS Rating: 2 out of 5 27.44

Caps

How do you think LOXO will perform against the market?

Add Stock to CAPS Watchlist

All Players

21 Outperform
7 Underperform
 

All-Star Players

8 Outperform
6 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top LOXO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

LOXO VS S&P 500 (SPY)

LOXO Summary

Fools bullish on LOXO are also bullish on:

Fools bearish on LOXO are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about LOXO.

Recs

0
Member Avatar Bigsef77 (68.47) Submitted: 1/7/2019 11:23:17 AM : Outperform Start Price: $131.51 LOXO Score: +78.16

Here's Why Loxo Oncology Is Skyrocketing Today
[Motley Fool]
Brian Feroldi, The Motley Fool
,Motley Fool•January 7, 2019
What happened

Shares of Loxo Oncology (NASDAQ: LOXO), a commercial-stage biopharma focused on cancer, jumped 66% as of 10:37 a.m. EST on Monday. The huge move is a response to the news that Loxo has agreed to be acquired by Eli Lilly and Company (NYSE: LLY) for a huge premium.
So what

Here are the key details of the proposed takeover offer:

Lilly has agreed to commence a tender offer to acquire all outstanding shares of Loxo Oncology for approximately $8 billion. That translates into a share price of $235, which is a 68% premium to Loxo's closing price on Friday, Jan. 4.
The deal will be paid for with cash.
Lilly will acquire any shares of Loxo Oncology that are not tendered by way of a second-step merger at the tender offer price.
The transaction is not subject to any financing condition.
The acquisition is expected to close by the end of the first quarter of 2019.

Lilly's management team stated that this deal makes sense because it will deepen the company's push into oncology.

Recs

0
Member Avatar RuthZweid (< 20) Submitted: 3/14/2018 5:18:47 PM : Outperform Start Price: $131.16 LOXO Score: +77.73



Thy h

Recs

0
Member Avatar fourladybugs (< 20) Submitted: 11/28/2015 4:54:20 PM : Outperform Start Price: $34.48 LOXO Score: +547.49

Cutting edge technology.

Leaderboard

Find the members with the highest scoring picks in LOXO.

Score Leader

sullyz0r

sullyz0r (65.66) Score: +2,202.59

The Score Leader is the player with the highest score across all their picks in LOXO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
sullyz0r 65.66 11/26/2014 Outperform 5Y $10.04 +2,237.25% +34.66% +2,202.59 1 Comment
jeepdrew2 46.22 4/17/2015 Outperform 5Y $12.91 +1,717.66% +33.60% +1,684.06 0 Comment
dollarsandcents1 < 20 10/2/2015 Outperform 5Y $17.28 +1,257.99% +47.32% +1,210.67 0 Comment
manirg < 20 10/31/2016 Outperform 5Y $20.43 +1,048.60% +31.09% +1,017.51 0 Comment
hhasia 61.41 5/19/2016 Outperform 5Y $25.61 +816.28% +36.79% +779.49 0 Comment
fourladybugs < 20 11/30/2015 Outperform 3Y $34.48 +580.57% +33.08% +547.49 1 Comment
portefeuille2 98.93 8/29/2017 Outperform 5Y $77.88 +201.31% +14.12% +187.19 0 Comment
portefeuille3 96.34 12/27/2017 Outperform 5Y $84.31 +178.35% +4.37% +173.98 0 Comment
golfinflyr < 20 1/22/2018 Outperform 5Y $97.50 +140.68% -0.37% +141.04 0 Comment
Bigsef77 68.47 3/13/2018 4/10/2018 Outperform 3Y $131.51 +78.44% +0.28% +78.16 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackOppenheimer 70.52 9/2/2014 Outperform NS $13.25 +1,671.02% +38.90% +1,632.12 0 Comment

Advertisement